Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by DJDawg on Oct 19, 2023 11:48am

warrants

Interesting discussion about warrants. I know that I've seen PR's that warrants have been extended. Can anyone clarify, the massive load of warrants from 4 years ago....can those be extended?

I can see it going both ways. If warrants are redeemed because the stock is above 0.35, that brings in something like 20m in funds which is a win. If they are not redeemed, then 57,500,000 fewer shares out there. That would prevent the shares outstanding from jumping by 25% if I understand it correctly.


Comment by 99942Apophis on Oct 19, 2023 1:06pm
Yes they can be extended DJDawg. One minor point that I feel has been brought up many times is share dilution which with share options and warrants  plus future options looking out say three years could roughly be 350 million give or take 10M.  Let's say Theralase achieve BTD before 2023 year end, followed by AA and gets a few Pharmaceutical partners (with more to join up) by end of ...more  
Comment by DJDawg on Oct 19, 2023 1:09pm
thanks for explaining that. I've always found warrants confusing as don't own any and never heard of them before this board.
Comment by patience69 on Oct 19, 2023 1:25pm
I could be wrong on this one but it seems to me that there is a 5 year maximum on warrants. These ones will be at 5 years when the August date arrives so I am not sure that they could be extended. The ones that just expired on October 3 were also at 5 years after being extended. They were in friendly hands but to the best of my knowledge they could not be extended past the 5 year mark
Comment by fecats on Oct 19, 2023 3:50pm
I believe you are correct P69 . It will be interesting to see what happens with warrants expiring Jan9/24 . They are at 5 years now as well after being extended a couple of times . They are 50 cent exercise price and I think about 4 million out there  . Lots can happen between now and then 
Comment by Rumpl3StiltSkin on Oct 19, 2023 4:56pm
These Jan warrants could get exercised in time as well. BTD should happen prior.
Comment by 99942Apophis on Oct 20, 2023 6:49am
My exact thoughts on the matter too all outstanding warrants will not need any extensions, end of story. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250